세계 녹내장 시장 규모는 2023년 85억 3,000만 달러에서 2031년 127억 5,000만 달러에 달할 것으로 예상되며, 예측 기간인 22024-2031년간 연평균 5.15% 성장할 것으로 예상됩니다. 녹내장 치료에 대한 시장 수요는 유병률 증가와 투자자 및 시장 기업의 관심 증가로 인해 예측 기간 동안 크게 성장할 것으로 예상됩니다.
녹내장은 시신경에 영향을 미치는 안질환군입니다. 시신경은 시각 정보를 눈에서 뇌로 전달하는 역할을 하며, 좋은 시력을 위해 필수적입니다. 녹내장은 보통 안압이 높아져 시신경이 손상되는 질환이지만, 정상 안압에서도 발병할 수 있습니다. 녹내장은 나이에 관계없이 발병할 수 있지만, 나이가 들수록 발병하기 쉽습니다. 녹내장은 60세 이상 실명의 주요 원인 중 하나입니다. 녹내장의 증상은 유형과 병기에 따라 다릅니다. 녹내장의 가장 흔한 유형은 개방각 녹내장이며, 폐쇄각 녹내장과 같은 다른 유형은 덜 흔합니다. 개방각 녹내장은 초기에는 자각증상이 없고 옆 시야에 점처럼 보이는 맹점이 보일 뿐입니다. 급성 폐쇄각 녹내장의 증상은 심한 두통, 시야 흐림, 충혈, 심한 눈의 통증, 메스꺼움, 구토 등입니다. 현재 전 세계적으로 8,000만 명이 녹내장을 앓고 있으며, 미국인 중 3천만 명 이상이 녹내장을 앓고 있고, 그 중 270만 명(40세 이상)이 개방각 녹내장으로 가장 흔한 질환이며, 2023년 6월에 발표된 Glaucoma Journal 보고서에 따르면 2040년까지 전 세계 녹내장 환자 수는 세계 녹내장 주간은 세계녹내장협회(World Glaucoma Association)가 주최하는 국제적인 행사로, 환자, 안과 의료진, 의료진, 지역 사회 및 환자, 그리고 안보건 전문가들이 함께 모여 녹내장에 대한 인식을 제고하는 자리입니다. 안과 의료진, 의료진, 지역사회에 전 세계 녹내장 옹호 활동 기획에 동참해 줄 것을 요청하고 있습니다. 녹내장은 예방 가능한 실명의 주요 원인이며, 전 세계 각 지역마다 고유한 과제가 존재합니다. 이 캠페인의 목표는 모든 사람들이 정기적으로 눈과 시신경을 검사하여 녹내장을 조기에 발견하고 시력 저하를 예방할 수 있는 치료를 시작할 수 있도록 하는 것입니다.
이 보고서는 세계 녹내장 시장을 조사 분석하여 시장 규모와 예측, 시장 역학, 주요 기업 현황 등을 제공합니다.
Global glaucoma market is projected to witness a CAGR of 5.15% during the forecast period 2024-2031, growing from USD 8.53 billion in 2023 to USD 12.75 billion in 2031. The market demand for glaucoma treatment is anticipated to thrive drastically in the forecast years due to rising prevalence and the growing interest of investors and market players.
Glaucoma is a group of eye conditions that affect the optic nerve. This optic nerve transmits visual information from your eye to your brain and is quintessential for good vision. Glaucoma is usually associated with damage to the optic nerve, often due to high pressure inside the eye, though it can occur with normal eye pressure. Glaucoma can be present at any age but occurs more often with advancing age. It is one of the major causes of blindness in patients older than 60 years of age. The symptoms of glaucoma are based on the type and stage of your condition. The most common type of glaucoma is open-angle glaucoma and other types are less common, like angle-closure glaucoma. Open-angle glaucoma shows no symptoms in early stage, just patchy blind spot in side vision. Acute angle-closure glaucoma symptoms are severe headache, blurred vision, eye redness, severe eye pain, nausea and vomiting. At present, there are 80 million people worldwide affected with glaucoma. More than 3 million Americans are affected with glaucoma; of these, 2.7 million (aged 40 and older) have its most common type, open-angle glaucoma. As per the report published in June 2023, by Glaucoma Journal, it is estimated that by 2040, there will be 22 million blind people around the world affected with glaucoma. The World Glaucoma Week is an international initiative organized by the World Glaucoma Association. They invite patients, eye care providers, health officials, and the community to partner together in planning advocacy activities globally. Glaucoma is the leading cause of preventable blindness, and unique challenges exist in various parts of the world. The goal here is to enlighten everyone to check their eyes and optic nerves regularly so that glaucoma can be detected as early as possible and treatment can begin to prevent vision loss.
Rising Prevalence of Glaucoma Disease
The increasing prevalence of glaucoma also poses public health concerns for reasons other than the aging global population. It is a leading cause of irreversible blindness, and its prevalence is expected to soar in the future. Factors involved include aging demographics - for example, an increasing population older than 60 years and the risk of developing glaucoma increases with age. In addition, increased knowledge and changes in the methods of diagnosis have led to a higher detection of the disease, which underlines the prevalence of the disease. Socioeconomic factors such as urbanization also play a key role. They can aggravate risk factors like hypertension and diabetes associated with glaucoma. Consequently, the control of the rising prevalence of the disease constitutes a significant aspect of public health efforts and healthcare systems in the worldr. For instance, on 22 September 2022, Santen and UBE announced the Food and Drug Administration approval for Omlonti (omidenepag isopropyl ophthalmic solution) 0.002% eye drops for the reduction of intraocular pressure in adults with open-angle glaucoma or ocular hypertension. Omlonti, the active pharmaceutical ingredient is omidenepag isopropyl, which is a relatively selective prostaglandin EP2 receptor agonist that increases aqueous humor drainage through the conventional (or trabecular) and uveoscleral outflow pathways.
Increasing Awareness and Advancement in Technology Brings Glaucoma Market Growth
Advanced treatments for glaucoma have dramatically changed the treatment of the disease, offering patients much more effective and targeted alternative therapies. Some of the recent innovations in pharmacotherapy involve entirely new classes of drugs, such as Rho kinase inhibitors, which represent an alternative means of lowering intraocular pressure. In addition, sustained-release drug delivery systems and implantable devices offer a degree of increased consistency with regard to adherence to any prescribed medication regimen and decreased side effects. Less-invasive surgical techniques, especially microinvasive glaucoma surgery (MIGS), have proven effective in the management of glaucoma with less time to recover and reduced morbidity compared with conventional surgeries. Such developments not only improve patient outcomes but also bring up the quality of life in patients suffering from the disease, thus making it crucial to continue further research and development work in this most critical area of eye care. For instance, in May 2024, Lupin Global, a pharmaceutical giant got approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for travoprost ophthalmic solution USP, 0.004% (ionic buffered solution). Travoprost ophthalmic solution USP, 0.004%, is indicated for lowering of intraocular pressure in patients diagnosed with open-angle glaucoma or ocular hypertension.
Rising Prevalence of Open Angle Glaucoma Segment to Dominate the Glaucoma Market
Open-angle glaucoma is expected to be a key driver for growth in this market in the face of the increasing incidence of open-angle glaucoma. Open Angle Glaucoma is the most common type of glaucoma and usually lacks symptoms in the early stages, thereby developing an increasing population that is untreated and undiagnosed as awareness increases. This is highly significant within aging populations, since the incidence of eye diseases is more prevalent within such populations. Advancements in diagnostic technologies and treatments, such as topical medications and surgical interventions, will continue to fuel further growth in the market. A focus on early detection and management of Open Angle Glaucoma to prevent vision loss is further likely to invest research and development efforts as well as increase patient education - which will have a positive impact on the market dynamics anticipated to rise in the future due to improved diagnostics facilities which enable more patients to be treated promptly. For instance, on 14 December 2022, Thea Pharma, Inc., the U.S. subsidiary of Europe's leading independent pharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval for the New Drug Application (NDA) of IYUZEH (latanoprost ophthalmic solution) 0.005% for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
North America Dominates the Glaucoma Market
North America currently dominates the glaucoma market, driven by a combination of advanced healthcare infrastructure, high awareness of eye health. Glaucoma is one of the major causes of irreversible blindness in the United States. More than 3 million Americans suffer from glaucoma. It is expected that by 2050, this number will increase to 6.3 million because of the aging US population. Glaucoma costs the US economy USD 2.86 billion every year through direct costs and loss of productivity. This region has a highly integrated network of ophthalmologists and eye care specialists that helps patients have proper treatment options at the right time. In terms of government initiatives and collaboration by private sectors, advanced treatments will be accessible. Robust reimbursement policies also sustain good care for patients. North America is likely to continue at the top, with its contribution expected to play a huge role in ongoing developments and new approaches for the prevention and management of glaucoma. For instance, on 15 December 2023, the United States Food and Drug Administration approved a new treatment for glaucoma, iDose TR (travoprost intracameral implant, 75 mcg). The new iDose TR is the first and only device of its kind that is specifically developed to offer up to three years of 24/7, continuous drug therapy directly inside the eye, helping patients suffering with glaucoma take control of the elevated eye pressure associated with this vision disease.
Future Market Scenario (2024-2031F)
The future market scenario for the glaucoma market appears promising and is characterized by significant advancements in technology and treatment options. The future of glaucoma management will change dramatically with emerging novel therapies, such as neuroprotective agents and minimally invasive surgical techniques. Ideally, telemedicine and other digital health solutions are expected to come in, making it easier for patients to adhere and monitor themselves. Moreover, increasing awareness and education will continue to result in earlier diagnoses. As a result, the prevalence of vision loss is likely to decrease. In addition, the increasing global demographics and an ageing population around the world will also increase demand for effective glaucoma treatments, resulting in significant demand and investment in the sector. For instance, sustained-release glaucoma drug delivery systems are currently being developed or are in the pipeline. Latanoprost punctal plug delivery system L-PPDS (Evolute, Mati Therapeutics, Austin, TX, USA) is a punctal plug loaded with prostaglandin analogs, it is currently in Phase II clinical trial.
Key Players Landscape and Outlook
Glaucoma market is mainly dominated by market players like Allergen Plc., Merck & Co., Inc. and many more. Market activity reported in recent years includes business agreements, collaborations, and regulatory approvals of market players' products. The market fosters several smaller players as well, which operate through collaborations with other players to cater to a larger market.
For instance, in May 2024, Merck (MRK.N) agreed to buy privately held biotech EyeBio for as much as USD 3 billion, in a deal aimed at adding treatments for eye diseases to the company's portfolio of experimental drugs. The maker will pay USD 1.3 billion in cash and another USD 1.7 billion in milestone-based payments upon future milestones with EyeBio, along with an agreement for access to a retinal disease drug called Restoret.
For instance, in July 2024, Alcon inks USD 466M deal for Belkin Vision's automated laser therapy for treat glaucoma. The deal includes an upfront payment of USD 81 million that includes about USD 65 million in cash-plus the chance at up to USD 385 million more in sales-based milestone payments, Alcon be able to get the technology into the hands of clinicians as first-line therapy.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.